Citizens reiterates CRISPR Therapeutics stock rating on gene editing prospects

Citizens reiterates CRISPR Therapeutics stock rating on gene editing prospects

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.